木瓜直播

The newly approved viloxazine extended-release capsules (Qelbree), a new selective norepinephrine reuptake inhibitor for the treatment of attention-deficit hyperactivity disorder in patients ages 6 to 17, in the U.S., Supernus Pharmaceuticals announced.

or a history of depression had poorer-quality relationships with their newborns. (ScienceDaily)

The FDA granted breakthrough therapy designation to the investigational , BI 425809, for the treatment of cognitive impairment associated with schizophrenia, based on the CONNEX phase III clinical program, Boehringer Ingelheim announced.

The agency also granted breakthrough device designation to , WB001, for the treatment of postpartum depression.

Latinx young adults may experience more , such as a racing heart. "This population also struggles with a lot of chronic physical health co-morbidities including heart disease and obesity, so this research is a good fit for a population who tends to blame mental health issues on physical ailments, which generates greater mental health risk," said study author Michael Zvolensky, PhD, of the University of Houston, in a . He was recently awarded a $2.7 million NIH grant to develop a behavioral healthcare app -- EASE (Easing Anxiety Sensitivity for Everyone) -- aimed at addressing in racial and ethnic groups. (Journal of Racial and Ethnic Health Disparities)

A new guide for pediatricians outlined the signs and symptoms to look for when identifying . (Pediatrics)

Children with autism whose parents were separated often got a -- on average 16 months later -- according to a new study. (Autism: The International Journal of Research and Practice)

Adamis Pharmaceuticals resubmitted its new drug application to the FDA for the company's , ZIMHI, for opioid overdose treatment.

Comment